|Bid||144.00 x 500|
|Ask||148.08 x 200|
|Day's Range||145.03 - 146.96|
|52 Week Range||139.36 - 192.64|
|PE Ratio (TTM)||64.99|
|Forward Dividend & Yield||0.92 (0.62%)|
|1y Target Est||N/A|
Shire plc’s (LSE:SHP) most recent return on equity was a substandard 2.31% relative to its industry performance of 25.47% over the past year. SHP’s results could indicate a relatively inefficientRead More...
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Shire Plc reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 3,822.03 million, Net Earnings of USD 246.41 million. Gross margins narrowed from 58.29% to 57.33% compared to the same period last year, operating (EBITDA) margins now 35.09% from 30.14%. Change in operating cash ... Read more (Read more...)
Shire filed an antitrust suit against Allergan, alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug.
In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.
Allergan Plc was sued on Monday by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease. In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra.
Shire plc (LSE:SHP) trades with a trailing P/E of 65.3x, which is higher than the industry average of 36.1x. While this makes SHP appear like a stock to avoid orRead More...
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Shire Plc with the following peers – Valeant Pharmaceuticals International Inc, Pfizer Inc., Johnson & Johnson, Eisai Co., Ltd. Sponsored ADR, Sanofi Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, CSPC Pharmaceutical Group Ltd. Sponsored ADR, Impax Laboratories, Inc., Sangamo Therapeutics, Inc. and Novartis AG ... Read more (Read more...)
Often enough, the departure of a company's chief financial officer is seen as bad news by investors. Why is Allergan gaining when companies like Red Hat (RHT) and Shire (SHPG) have dropped after similar announcements? Chalk it up to Allergan's announcement that it would use its free cash flow to buy back stock instead of on acquisitions, as well as pay down debt and increase the dividend.
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.
Although the biopharmaceutical giant's more recently launched products did well last quarter, sagging sales of two older drugs made investors nervous.
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.
Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.
Shire PLC's ADHD business has been at its core for years and helped it afford last year's transformative, $35 billion dollar purchase of Baxalta Inc.